Swipe om te navigeren naar een ander artikel
Medication adherence in children is poor, particularly among those with chronic or mental health disorders. However, adherence has not been fully assessed in autism spectrum disorders (ASDs). The validated proportion of days covered method was used to quantify adherence to psychotropic medication in Medicaid-eligible children who met diagnostic criteria for ASD between 2000 and 2008 (N = 628). Among children prescribed attention deficit hyperactivity disorder (ADHD) medications, antidepressants, or antipsychotics, 44, 40 and 52 % were adherent respectively. Aggressive behaviors and abnormalities in eating, drinking, and/or sleeping, co-occurring ADHD, and the Medication Regimen Complexity Index were the most significant predictors of adherence rather than demographics or core deficits of ASD. Identifying barriers to adherence in ASD may ultimately lead to improved treatment outcomes.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Allison, P. (2001). Logistic regression using the SAS system: Theory and application (p. 48). Cary: Wiley-SAS.
American Psychiatric Association (APA). (2000). Diagnostic and statistical manual of mental disorder, fourth edition, text revision. Washington, DC: American Psychiatric Association.
Arney, J., Street, R. J., et al. (2012). Factors shaping physicians’ willingness to accomodate medication requests. Evaluations & the Health Professions [Epub ahead of print].
Bunch, B. (2008). South Carolina Department of Commerce. Division of Research. Developing a rural definition, analysis of South Carolina counties. http://sccommerce.com/sites/default/files/document_directory/Rural_Definition_Developing_a_Rural_Definition_for_South_Carolina_Analysis_of_South_Carolina_Counties_2008.pdf.
Canas, F., Alptekin, K., et al. (2013). Improving treatment adherence in your patients with Schizophrenia: The STAY initiative. Clinical Drug Investigation, 33(2), 97–107.
CDC. (2012). Prevalence of autism spectrum disorders—Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Morbidity and Mortality Weekly Report, 61(SS03), 1–19.
Census, US. (2013). US Office of Management and Budget. http://www.census.gov/population/www/estimates/metroarea.html. Accessed September 03, 2013.
Chavira, D., et al. (2003). Parental opinions regarding treatment for social anxiety disorder in youth. Journal of Developmental and Behavioral, 24(5), 315–322.
Ciechanowski, P., Katon, W., et al. (2000). Depression and diabetes: Impact of depressives symptoms on adherence, function, and costs. Archives of Internal Medicine, 27, 3278–3285. CrossRef
CMS. (2011). New medicare part D patient safety report—Antiret-roviral adherence. Baltimore, Maryland: Department of Health and Human Services. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/downloads/MemoPtSafetyRepor_122911.pdf.
Courrege, D. (2012). Charleston special education review turns up problems, commendations. The Post and Courier. Charleston, SC. http://www.postandcourier.com/article/20120407/UNKNOWN/120409293. Accessed 03 September 2013.
Cramer, J., et al. (2007). Medication compliance and persistence: terminology and definitions. Value in Health. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Medication Compliance and Persistence Work Group, 11, 44–47.
Dawson, G. (2013). Dramatic increase in autism prevalence parallels explosion of research into its biology and causes. Archives of General Psychiatry, 70(1), 9–10. doi: 10.1001/jamapsychiatry.2013.488.
Dilorio, C., Yeager, K., Shafer, P. O., Letz, R., Henry, T., Schomer, D. L., et al. (2003). The epilepsy medication and treatment complexity index: Reliability and validity testing. Journal of Neuroscience Nursing, 35(3), 155–162. CrossRef
Durkin, M., Maenner, M., Meaney, F., Levy, S. E., DiGuiseppi, C., Nicholas, J. S., et al. (2010). Socioeconomic inequality in the prevalence of autism spectrum disorder: Evidence from a US cross-sectional study. PLoS ONE, e11511.
Esbensen, A., Greenberg, J., et al. (2009). A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. Journal of Autism and Developmental Disorders, 39(9), 1339–1349.
Farley, J., Hansen, R., et al. (2012). Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions. The Primary Care Companion to CNS Disorders. doi: 10.4088/PCC.11m01324.
Faught, E., Duh, M., et al. (2008). Nonadherence to antiepileptic drugs and increased mortality findings from the RANSOM Study. Neurology, 17(20), 1572–1578. CrossRef
FDA. (2006). NDA 20‐272 / S‐036, 20‐588 / S‐024, 21‐444 / S‐008: Final Agreed‐Upon Labeling. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021444s008s015,020588s024s028s029,020272s036s041lbl.pdf.
FDA. (2008). New or modified indication. Label and Approval History of Strattera (Atomoxetine Hydrochloride). Letter 5/2008 by Lilly. http://fdazilla.com/drugs/appdoc/19799.
FDA. (2009). New indication approval for Abilify (aripiprazole). Supplemental Letter. NDA 021436/S‐027. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021436s027ltr.pdf.
Friedman, L., Furberg, C., et al. (2010). Fundamentals of clinical trials. New York, Heidelberg: Springer, 251–267. CrossRef
Gau, S., Shen, H., et al. (2006). Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. Journal of Child & Adolescent Psychopharmacology, 16, 286–297. CrossRef
Hastie, T., Tibshirani, R., et al. (2009). The elements of statistical learning: Data mining, inference, and prediction (2nd ed.). New York: Springer.
Karve, S., Cleves, M., Helm, M., Hudson, T. J., West, D. S., & Martin, B. C. (2008). An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Medical Care, 46(11), 25–33. CrossRef
Karve, S., Cleves, M., Helm, M., Hudson, T. J., West, D. S., & Martin, B. C. (2009a). Good and poor adherence: Optimal cut-point for adherence measures using administrative claims data. Current Medical Research and Opinion, 25(9), 2302–2310. CrossRef
Kelley, S. O. (1988). Measurement of the complexity of medication regimens of the elderly. University of Missouri-Columbia. pp. 23–58.
King, L., Nicholas, J., et al. (2008). Characteristics of autism spectrum disorders over time, surveillance results from children born between 1992 and 2002. AEP, 18(9), 724–725.
Lazaratou, H., Anagnostopoulos, D., et al. (2007). Parental attitudes and opinions on the use of psychotropic medication in mental disorders of childhood. Annals of General Psychiatry, 6(32). doi: 10.1186/1744-859X-6-32.
Leslie, R. S. (2008). Calculating medication compliance, adherence, and persistence in administrative pharmacy claims databases. http://www.wuss.org/proceedings08/08WUSS%20Proceedings/papers/anl/anl09.pdf. Accessed September 03, 2013.
Leslie, R. S., Gwadry-Sridhar, F., et al. (2008). Calculating medication compliance, adherence, and persistence in administrative pharmacy claims databases. Pharmaceutical Programming, 1(1), 13–19. CrossRef
Levy, S., Giarelli, E., et al. (2010). Autism spectrum disorder and co-occurring developmental, psychiatric, medical conditions among children in multiple populations of the United States. Journal of Developmental and Behavioral Pediatrics, 31, 267–275.
Marcus, S. (2011). Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 50(5), 480–489.
Martin, S., Wolters, P., Calabrese, S. K., Toledo-Tamula, M. A., Wood, L. V., Roby, G., et al. (2007). The antiretroviral regimen complexity index: A novel method of quantifying regimen complexity. Journal of Acquired Immune Deficiency Syndromes, 15(45), 535–544. CrossRef
McPheeter, M., Warren, Z., et al. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127(4), e1312–e1321. CrossRef
Meltzer, H. Y., Lindenmayer, J. P., Kwentus, J., Share, D. B., Johnson, R., & Jayathilake, K. (2014). A six month randomized controlled trial of long acting injectable risperidone 50 and 100 mg in treatment resistant schizophrenia. Schizophrenia Research, 154(1–3), 14–22. doi: 10.1016/j.schres.2014.02.15.
Ming, X., Brimacombe, M., et al. (2008). Autism spectrum disorders: Concurrent clinical disorders. Journal of Child Neurology, 23(1), 6–13.
Mire, S., Nowell, K., Kubiszyn, T., & Goin-Kochel, R. (2013). Psychotropic medication use among children with autism spectrum disorders within the Simons Simplex Collection: Are core features of autism spectrum disorder related? Autism, 18(3). doi: 10.1177/1362361313498518.
Mitchell, W., Scheeier, L., et al. (2000). Adherence to treatment in children with epilepsy: Who follows “doctor’s orders?”. Epilepsia, 41(12), 616–625.
Nau, D. (2012). The importance of measuring adherence. PQA. https://www.urac.org/consumers/resources/Includes/Nau_Presentation from https://www.urac.org/consumers/resources/Includes/Nau_Presentation.pdf. Accessed September 03, 2013.
NCQA. (2011). Use and continuity of antipsychotic medications for treatment of schizohrenia. http://www.ncqa.org/portals/0/hedisqm/Use%20and%20Continuity%20of%20APs.pdf. Accessed September 03, 2013.
OARC. (2012). Analysis report: The global landscape of autism research. Office of Autism Research Coordination (OARC). National Institute of Mental Health. Thomas Reuters, Interagency Autism Coordinating Committee (IACC).
Olaniyan, O., dosReis, R., et al. (2007). Community perspectives of childhood behavioral problems and ADHD among African American parents. Ambulatory Pragmatics, 7(3), 226–231.
Patel, N., DelBello, M., et al. (2005). Ethnic differences in maintenance antipsychotic prescription among adolescents with bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 16(6), 938–946. CrossRef
Powell, K. C., Van Naarden Braun, K., Singh, R. H., Shapira, S. K., Olney, R. S., & Yeargin-Allsopp, M. (2010). Prevalence of developmental disabilities and receipt of special education services among children with an inborn error of metabolism. Pediatrics, 156, 420–426. CrossRef
Schatzberg, A., Cole, J., et al. (2010). Manual of clinical psychopharmacology. Arlington, VA: American Psychiatric Publishing.
Shah, N. (2011). Feds threaten S.C. with $111 million cut to special ed. Education Week. http://blogs.edweek.org/edweek/speced/2011/06/another_state_denied_power_to.html. Accessed September 03, 2013.
Stone, V., Hogan, J., et al. (2001). Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: Survey of women in the HER study. JAIDS, 28(2), 124–131. PubMed
Taylor, J., Dove, D., et al. (2012). Interventions for adolescents and young adults with autism spectrum disorders. A. f. H. R. a. Qualtiy. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I.) AHRQ Publication No. 12-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. August 2012. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed September 03, 2013.
Van Narden Braun, K., et al. (2008). Relationships between multiple births and autism spectrum disorders, cerebral palsy, and intellectual disabilities: Autism and developmental disabilities monitoring (ADDM) network—2002 surveillance year. Autism Research, 1(5), 265–316. CrossRef
Volkmar, F., & Wiesner, L. (2009). A practical guide to autism: What every parent, family member and teacher needs to know (pp. 458–459). Hoboken, NJ: Wiley.
Warren, Z., Veenstra-VanderWeele, J., et al. (2011). Therapies for children with autism spectrum disorders. Comparative effectiveness reviews (No. 26), Rockville (MD): Agency for Healthcare Research and Quality (US). http://www.ncbi.nlm.nih.gov/books/NBK56343/.
WHO. (2003). Adherence to long-term therapies—Evidence for action. WHO Library Cataloguing-inPublication Data. http://apps.who.int/medicinedocs/en/d/Js4883e/. Accessed September 03, 2013.
WHO. (2005). Improving access and use of psychotropic medicines. Mental health policy and service guidance package (pp. 8–10). Geneva: WHO. http://www.imhcn.org/wpcontent/uploads/2014/04/improving_access_final_10_01_05.pdf.
WHO and Macroeconomics and Health: Investing in Health for Economic Development. (2001). Report of the Commission on Macroeconomics and Health (pp. 8–83). Geneva: World Health Organization. http://whqlibdoc.who.int/publications/2001/924154550x.pdf.
- Rates and Predictors of Adherence to Psychotropic Medications in Children with Autism Spectrum Disorders
Sarah L. Logan
R. Scott Leslie
Kelly S. Hunt
Joyce S. Nicholas
- Springer US